HOOKIPA Pharma Inc. (HOOK)
NASDAQ: HOOK · IEX Real-Time Price · USD
6.42
+0.07 (1.10%)
At close: Jul 19, 2024, 4:00 PM
6.43
+0.01 (0.16%)
Pre-market: Jul 22, 2024, 8:54 AM EDT
HOOKIPA Pharma Employees
As of December 31, 2023, HOOKIPA Pharma had 179 total employees, including 151 full-time and 28 part-time employees. The number of employees increased by 1 or 0.56% compared to the previous year.
Employees
179
Change (1Y)
1
Growth (1Y)
0.56%
Revenue / Employee
$299,173
Profits / Employee
-$265,458
Market Cap
61.99M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Prenetics Global | 324 |
Vor Biopharma | 168 |
Allakos | 131 |
ProPhase Labs | 113 |
VolitionRx | 110 |
InspireMD | 66 |
Entera Bio | 18 |
SELLAS Life Sciences Group | 16 |
HOOK News
- 56 minutes ago - HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200 - GlobeNewsWire
- 14 days ago - HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split - GlobeNewsWire
- 20 days ago - HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV - GlobeNewsWire
- 6 weeks ago - HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting - GlobeNewsWire
- 7 weeks ago - HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 3 months ago - HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab - GlobeNewsWire